# Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders

**Authors:** Flavia Indrio, Antonio Di Mauro, Giacomo Perrone, Annamaria Greco, Simona Filoni, Enea Vincenzo Napolitano, Luca Pecoraro

PMC · DOI: 10.3390/nu18040687 · Nutrients · 2026-02-20

## TL;DR

Giving a specific probiotic to infants may reduce their risk of developing chronic abdominal pain disorders in childhood.

## Contribution

A 10-year follow-up shows long-term benefits of early probiotic use in preventing functional abdominal pain.

## Key findings

- Probiotic group had 13.1% FAP vs 80.2% in placebo group at age 10.
- Early L. reuteri use was associated with a 67.1% absolute risk reduction in FAP.
- Results suggest a strong association but not definitive causality due to study limitations.

## Abstract

Introduction: Pediatric Functional Gastrointestinal Disorders (FGIDs), including infantile colic and constipation, may persist into later childhood and adulthood, sometimes manifesting as functional abdominal pain (FAP). Early exposure to probiotics during critical developmental windows may influence long-term susceptibility to disease. Background/Objectives: Building on our original randomized controlled trial, which demonstrated that Lactobacillus reuteri DSM 17938 reduced acute infantile FGID symptoms, a 10-year follow-up study was performed to evaluate whether this early intervention provided lasting protection against FAP in childhood. Methods: Two hundred participants from the original RCT cohort completed follow-up assessments at age ten. The primary outcome was the presence of FAP, analyzed according to the original randomization group (probiotic vs placebo). FAP was diagnosed at age 10 using the Rome IV criteria, based on a standardized clinical assessment by a pediatric gastroenterologist who was blinded to the original allocation. Results: FAP was diagnosed in 13/99 (13.1%) children in the probiotic group and 81/101 (80.2%) in the placebo group, corresponding to an absolute risk reduction of 67.1% (95% CI 56.8–77.3) and a relative risk of 0.16 (95% CI 0.10–0.27) (p < 0.001). Conclusions: Early supplementation with L. reuteri DSM 17938 was associated with a markedly lower prevalence of FAP at age 10. However, the long-term follow-up was observational and characterized by a 57.2% attrition rate. In addition, longitudinal data on potential confounders were unavailable; therefore, the findings should be interpreted as an association rather than proof of causality.

## Linked entities

- **Diseases:** constipation (MONDO:0002203), FAP (MONDO:0021055)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Diseases:** irritable bowel syndrome (MESH:D043183), inflammatory bowel disease (MESH:D015212), chronic pain (MESH:D059350), organic disease (MESH:D000092124), allergic and neurobehavioral disorders (MESH:D019954), constipation (MESH:D003248), visceral hypersensitivity (MESH:D004342), dyspepsia (MESH:D004415), colic (MESH:D003085), abdominal migraine (MESH:D008881), celiac disease (MESH:D002446), gastrointestinal bleeding (MESH:D006471), vomiting (MESH:D014839), gastrointestinal symptoms (MESH:D012817), inflammation (MESH:D007249), injury to (MESH:D014947), pain (MESH:D010146), infections (MESH:D007239), growth failure (MESH:D051437), post-infectious functional syndromes (MESH:D000094025), FGIDs (MESH:D005767), Abdominal Pain Disorders (MESH:D015746), weight loss (MESH:D015431)
- **Chemicals:** short-chain fatty acids (MESH:D005232), L. reuteri DSM 17938 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943314/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12943314/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943314/full.md

---
Source: https://tomesphere.com/paper/PMC12943314